

VIAVIENTE GLOBAL

REPORT NO: FA/2011/51208A-01

Date: 2011/05/23



The following sample(s) was/were submitted and identified by/on behalf of client as:

Sample Name : Natural Whole Fruit Puree
Application : VIAVIENTE GLOBAL
Manufacturer/Vendor: VIAVIENTE GLOBAL
Country of Origin: USA
Date of Sample Received: 2011/05/12
Date of Testing: 2011/05/13

Test Requested: Qualitative analysis of 224 Chemicals for clinical use.

Test Method: With reference to Ann Rept. BFDA Taiwan R.O.C. 23 : 136-148 2005 , and Journal of Pharmaceutical and Biomedical Analysis Volume 40, Issue 2, 13 February 2006, Pages 305-311. Analysis was performed by LC/MS.

Test Results: The sample is non-detected in 224 Chemicals for clinical use(see appendix).

NOTE : 1.The report is separated for used in vain.
 2.The test result over detection limit is summarized in the table. All test items and detection limits are listed in appendix.



Unless otherwise stated the results shown in this test report refer only to the sample(s) tested. This test report cannot be reproduced, except in full, without prior written permission of the Company. 除非另有說明，此報告結果僅對測試的樣品負責。本報告未經本公司書面許可，不可部份複製。
 This document is issued by the Company subject to its General Conditions of Service printed overleaf, available on request or accessible at www.sgs.com/terms_and_conditions.htm and for electronic format documents, subject to Terms and Conditions for Electronic Documents at www.sgs.com/terms_e-document.htm. Attention is drawn to the limitation of liability, indemnification and jurisdiction issues defined therein. Any holder of this document is advised that information contained hereon reflects the Company's findings at the time of its intervention only and within the limits of Client's instructions, if any. The Company's sole responsibility is to its Client and this document does not exonerate parties to a transaction from exercising all their rights and obligations under the transaction documents. This document cannot be reproduced except in full, without prior written approval of the Company. Any unauthorized alteration, forgery or falsification of the content or appearance of this document is unlawful and offenders may be prosecuted to the fullest extent of the law.

VIAVIENTE GLOBAL

REPORT NO: FA/2011/51208A-01

Date: 2011/05/23



Appendix

Test items & MDL List : Unit:ppm(mg/k)

| Test Items | Kind | MDL | Test Items | Kind | MDL |
|-------------------------|----------------------|-----|-----------------------------|-------------|-----|
| Digitoxin | Cardiovascular Drugs | 100 | Sulfamethazine | Antibiotics | 10 |
| Dipyridamole | Cardiovascular Drugs | 10 | Sulfamethizole | Antibiotics | 100 |
| Nylidrin | Cardiovascular Drugs | 10 | Sulfamethoxazole | Antibiotics | 10 |
| Papaverine | Cardiovascular Drugs | 100 | Sulfamethoxyppyridazine | Antibiotics | 10 |
| Aminophylline | Bronchodilators | 100 | Sulfanilamide | Antibiotics | 100 |
| Theophylline | Bronchodilators | 100 | Sulfathiazole | Antibiotics | 10 |
| Clenbuterol | Bronchodilators | 10 | Sulfisoxazole | Antibiotics | 100 |
| Dyphylline | Bronchodilators | 100 | Terbinafine | Antibiotics | 10 |
| Chlormezanone | Muscle Relaxants | 20 | Tinidazole | Antibiotics | 10 |
| Chlorzoxazone | Muscle Relaxants | 10 | Tetracycline | Antibiotics | 20 |
| Orphenadrine | Muscle Relaxants | 10 | Trimethoprim | Antibiotics | 10 |
| Carisoprodol | Muscle Relaxants | 10 | Benzathine-benzylpenicillin | Antibiotics | 250 |
| Benzocaine | Local Anesthetics | 50 | Clindamycin phosphate | Antibiotics | 20 |
| Dibucaine | Local Anesthetics | 10 | Cloxacillin Sodium | Antibiotics | 20 |
| Diclofenac diethyl salt | Local Anesthetics | 30 | Chlortetracycline | Antibiotics | 20 |
| Lidocaine | Local Anesthetics | 10 | Dimetridazole | Antibiotics | 100 |
| Procaine | Local Anesthetics | 10 | Enrofloxacin | Antibiotics | 10 |
| Tetracaine | Local Anesthetics | 10 | Lincomycin | Antibiotics | 10 |
| Econazole | Antibiotics | 10 | Difloxacin | Antibiotics | 10 |
| Griseofulvin | Antibiotics | 10 | Ofloxacin | Antibiotics | 10 |
| Lomefloxacin | Antibiotics | 10 | Oxytetracycline (OTC) | Antibiotics | 20 |
| Ketoconazole | Antibiotics | 20 | Sulfisomidine | Antibiotics | 10 |
| Metronidazole | Antibiotics | 10 | Santonin | Antibiotics | 50 |
| Nalidixic acid | Antibiotics | 10 | Ampicillin | Antibiotics | 20 |
| Minocycline | Antibiotics | 20 | Amoxicillin | Antibiotics | 200 |
| Quinine | Antibiotics | 10 | Clindamycin | Antibiotics | 10 |
| Sulfaquinolaxaline | Antibiotics | 20 | Ceftriaxone | Antibiotics | 100 |
| Sulfamonomethoxine | Antibiotics | 20 | Doxycycline | Antibiotics | 20 |
| Sulfadiazine | Antibiotics | 20 | Erythromycin | Antibiotics | 10 |
| Sulfadimethoxine | Antibiotics | 10 | Rifampin | Antibiotics | 10 |
| Sulfamerazine | Antibiotics | 10 | Cephradine | Antibiotics | 50 |

Unless otherwise stated the results shown in this test report refer only to the sample(s) tested. This test report cannot be reproduced, except in full, without prior written permission of the Company. 除非另有說明，此報告結果僅對測試的樣品負責。本報告未經本公司書面許可，不可部份複製。

This document is issued by the Company subject to its General Conditions of Service printed overleaf, available on request or accessible at www.sgs.com/terms_and_conditions.htm and, for electronic format documents, subject to Terms and Conditions for Electronic Documents at www.sgs.com/terms_e-document.htm. Attention is drawn to the limitation of liability, indemnification and jurisdiction issues defined therein. Any holder of this document is advised that information contained hereon reflects the Company's findings at the time of its intervention only and within the limits of Client's instructions, if any. The Company's sole responsibility is to its Client and this document does not exonerate parties to a transaction from exercising all their rights and obligations under the transaction documents. This document cannot be reproduced except in full, without prior written approval of the Company. Any unauthorized alteration, forgery or falsification of the content or appearance of this document is unlawful and offenders may be prosecuted to the fullest extent of the law.

VIAVIENTE GLOBAL

REPORT NO: FA/2011/51208A-01

Date: 2011/05/23



Appendix

Test items & MDL List : Unit:ppm(mg/k)

| Test Items | Kind | MDL | Test Items | Kind | MDL |
|---------------------|----------------------------------------|-----|-------------------------|------------------------|-----|
| Chloramphenicol | Antibiotics | 10 | Reserpine | Antihypertensive Drugs | 10 |
| Nitrofurantoin | Antibiotics | 100 | Timolol Maleate | Antihypertensive Drugs | 10 |
| Brompheniramine | Antihistaminics | 10 | Methyldopa | Antihypertensive Drugs | 100 |
| Carbinoxamine | Antihistaminics | 10 | Methamphetamine | CNS Stimulants | 10 |
| Chlorpheniramine | Antihistaminics | 10 | Morphine | CNS Stimulants | 100 |
| Diphenhydramine | Antihistaminics | 10 | Pentazocine | CNS Stimulants | 10 |
| Terfenadine | Antihistaminics | 10 | Phenylephrine | CNS Stimulants | 100 |
| Cyproheptadine | Antihistaminics | 10 | Strychnine | CNS Stimulants | 10 |
| Cetirizine 2HCl | Antihistaminics | 10 | Theobromine | CNS Stimulants | 50 |
| Chlorothiazide | Urinary system Drugs | 10 | Diethylstilbestrol | Hormone Drugs | 200 |
| Flavoxate | Urinary system Drugs | 10 | Estriol | Hormone Drugs | 100 |
| Furosemide | Urinary system Drugs | 10 | Estrone | Hormone Drugs | 50 |
| Hydrochlorothiazide | Urinary system Drugs | 500 | Ethisterone | Hormone Drugs | 10 |
| Phenazopyridine | Urinary system Drugs | 10 | Ethylestrenol | Hormone Drugs | 500 |
| Oxybutynin | Urinary system Drugs | 250 | Fluoxymesterone | Hormone Drugs | 10 |
| Sulfinyprazole | Urinary system Drugs | 10 | Methandriol | Hormone Drugs | 100 |
| Carbimazole | Thyroid hormone and antithyroid agents | 200 | Methandrostenolone | Hormone Drugs | 10 |
| Liothyronine | Thyroid hormone and antithyroid agents | 10 | Methyltestosterone | Hormone Drugs | 10 |
| Methimazole | Thyroid hormone and antithyroid agents | 100 | Nandrolone | Hormone Drugs | 200 |
| Bezafibrate | Antilipemic Drugs | 10 | Norethisterone | Hormone Drugs | 10 |
| Clofibrate | Antilipemic Drugs | 50 | Oxymetholone | Hormone Drugs | 100 |
| Etofibrate | Antilipemic Drugs | 10 | Progesterone | Hormone Drugs | 10 |
| Fenofibrate | Antilipemic Drugs | 10 | Stanozolol | Hormone Drugs | 10 |
| Gemfibrozil | Antilipemic Drugs | 500 | Testosterone | Hormone Drugs | 100 |
| Nicametate | Antilipemic Drugs | 50 | Testosterone propionate | Hormone Drugs | 10 |
| Xanthinol Niacinate | Antilipemic Drugs | 10 | Metoclopramide | Gastrointestinal Drugs | 250 |
| Atenolol | Antihypertensive Drugs | 10 | Atropine | Gastrointestinal Drugs | 10 |
| Hydralazine | Antihypertensive Drugs | 100 | Bisacodyl | Gastrointestinal Drugs | 10 |
| Minoxidil | Antihypertensive Drugs | 20 | Butropium | Gastrointestinal Drugs | 10 |
| Nifedipine | Antihypertensive Drugs | 10 | Camylofine | Gastrointestinal Drugs | 10 |
| Propranolol | Antihypertensive Drugs | 10 | Cimetidine | Gastrointestinal Drugs | 10 |

Unless otherwise stated the results shown in this test report refer only to the sample(s) tested. This test report cannot be reproduced, except in full, without prior written permission of the Company. 除非另有說明，此報告結果僅對測試的樣品負責。本報告未經本公司書面許可，不可部份複製。

This document is issued by the Company subject to its General Conditions of Service printed overleaf, available on request or accessible at www.sgs.com/terms_and_conditions.htm and, for electronic format documents, subject to Terms and Conditions for Electronic Documents at www.sgs.com/terms_e-document.htm. Attention is drawn to the limitation of liability, indemnification and jurisdiction issues defined therein. Any holder of this document is advised that information contained hereon reflects the Company's findings at the time of its intervention only and within the limits of Client's instructions, if any. The Company's sole responsibility is to its Client and this document does not exonerate parties to a transaction from exercising all their rights and obligations under the transaction documents. This document cannot be reproduced except in full, without prior written approval of the Company. Any unauthorized alteration, forgery or falsification of the content or appearance of this document is unlawful and offenders may be prosecuted to the fullest extent of the law.

VIAVIENTE GLOBAL

REPORT NO: FA/2011/51208A-01

Date: 2011/05/23



Appendix

Test items & MDL List : Unit:ppm(mg/k)

| Test Items | Kind | MDL | Test Items | Kind | MDL |
|------------------|-----------------------------|-----|-------------------|-----------------------------------|------|
| Dicyclomine | Gastrointestinal Drugs | 10 | Benzydamine | Antipyretics and Analgesics | 10 |
| Glycopyrronium | Gastrointestinal Drugs | 10 | Bufexamac | Antipyretics and Analgesics | 100 |
| Homatropine | Gastrointestinal Drugs | 10 | Fenbufen | Antipyretics and Analgesics | 200 |
| Oxethazaine | Gastrointestinal Drugs | 10 | Flufenamic acid | Antipyretics and Analgesics | 10 |
| Oxyphencyclimine | Gastrointestinal Drugs | 10 | Niflumic acid | Antipyretics and Analgesics | 10 |
| Phenolphthalein | Gastrointestinal Drugs | 10 | Cinnarizine | Central Nerves System Depressants | 10 |
| Pirenzepine | Gastrointestinal Drugs | 10 | Amitriptyline | Central Nerves System Depressants | 10 |
| Propantheline | Gastrointestinal Drugs | 10 | Amphetamine | Central Nerves System Depressants | 200 |
| Ranitidine | Gastrointestinal Drugs | 10 | Benzhexol | Central Nerves System Depressants | 10 |
| Scopolamine | Gastrointestinal Drugs | 10 | Bromisovalum | Central Nerves System Depressants | 200 |
| Acetaminophen | Antipyretics and Analgesics | 100 | Chlorpromazine | Central Nerves System Depressants | 10 |
| Allopurinol | Antipyretics and Analgesics | 250 | Cocaine | Central Nerves System Depressants | 10 |
| Aminopyrine | Antipyretics and Analgesics | 10 | Diazepam | Central Nerves System Depressants | 10 |
| Aspirin | Antipyretics and Analgesics | 20 | Diphenylhydantoin | Central Nerves System Depressants | 100 |
| Benzbromarone | Antipyretics and Analgesics | 20 | Fluoxetine | Central Nerves System Depressants | 10 |
| Bucetin | Antipyretics and Analgesics | 10 | Lorazepam | Central Nerves System Depressants | 25 |
| Colchicine | Antipyretics and Analgesics | 10 | Melatonin | Central Nerves System Depressants | 20 |
| Ethoxybenzamide | Antipyretics and Analgesics | 10 | Mephenesin | Central Nerves System Depressants | 100 |
| Flurbiprofen | Antipyretics and Analgesics | 250 | Meprobamate | Central Nerves System Depressants | 100 |
| Ibuprofen | Antipyretics and Analgesics | 500 | Metharbital | Central Nerves System Depressants | 200 |
| Indomethacin | Antipyretics and Analgesics | 10 | Phenobarbital | Central Nerves System Depressants | 1000 |
| Ketoprofen | Antipyretics and Analgesics | 20 | Quetiapine | Central Nerves System Depressants | 10 |
| Mefenamic acid | Antipyretics and Analgesics | 50 | Primidone | Central Nerves System Depressants | 20 |
| Naproxen | Antipyretics and Analgesics | 50 | Secobarbital | Central Nerves System Depressants | 500 |
| Oxyphenbutazone | Antipyretics and Analgesics | 10 | Thioridazine | Central Nerves System Depressants | 10 |
| Phenylbutazone | Antipyretics and Analgesics | 10 | Zolpidem | Central Nerves System Depressants | 10 |
| Piroxicam | Antipyretics and Analgesics | 10 | Haloperidol | Central Nerves System Depressants | 10 |
| Probenecid | Antipyretics and Analgesics | 10 | Sulpiride | Central Nerves System Depressants | 10 |
| Salicylamide | Antipyretics and Analgesics | 100 | Cephalexin | Central Nerves System Depressants | 20 |
| Sulindac | Antipyretics and Analgesics | 10 | Cefazolin | Central Nerves System Depressants | 20 |
| Acetophenetidin | Antipyretics and Analgesics | 10 | Acetohexamide | Antidiabetics | 200 |

Unless otherwise stated the results shown in this test report refer only to the sample(s) tested. This test report cannot be reproduced, except in full, without prior written permission of the Company. 除非另有說明，此報告結果僅對測試的樣品負責。本報告未經本公司書面許可，不可部份複製。

This document is issued by the Company subject to its General Conditions of Service printed overleaf, available on request or accessible at www.sgs.com/terms_and_conditions.htm and, for electronic format documents, subject to Terms and Conditions for Electronic Documents at www.sgs.com/terms_e-document.htm. Attention is drawn to the limitation of liability, indemnification and jurisdiction issues defined therein. Any holder of this document is advised that information contained hereon reflects the Company's findings at the time of its intervention only and within the limits of Client's instructions, if any. The Company's sole responsibility is to its Client and this document does not exonerate parties to a transaction from exercising all their rights and obligations under the transaction documents. This document cannot be reproduced except in full, without prior written approval of the Company. Any unauthorized alteration, forgery or falsification of the content or appearance of this document is unlawful and offenders may be prosecuted to the fullest extent of the law.

VIAVIENTE GLOBAL

REPORT NO: FA/2011/51208A-01

Date: 2011/05/23



Appendix

Test items & MDL List : Unit:ppm(mg/k)

| Test Items | Kind | MDL | Test Items | Kind | MDL |
|------------------------|---------------------------|-----|-----------------------|-------|-----|
| Chlorpropamide | Antidiabetics | 10 | Finasteride | Other | 10 |
| Glibenclamide | Antidiabetics | 10 | Hydroxyvardenafil | Other | 10 |
| Metformin | Antidiabetics | 10 | Imidazosagatriazinone | Other | 10 |
| Phenformin | Antidiabetics | 10 | Norneosildenafil | Other | 10 |
| Pioglitazone | Antidiabetics | 10 | Phentermine | Other | 10 |
| Tolazamide | Antidiabetics | 10 | Phentolamine | Other | 10 |
| Gliclazide | Antidiabetics | 20 | Phenylpropanolamine | Other | 500 |
| Tolbutamide | Antidiabetics | 10 | Salicylic acid | Other | 250 |
| Bromhexine | Antitussives&Expectorants | 10 | Yohimbine | Other | 10 |
| Carbetapentane | Antitussives&Expectorants | 10 | - blank space below- | | |
| Dextromethorphan | Antitussives&Expectorants | 10 | | | |
| Guaifenesin | Antitussives&Expectorants | 10 | | | |
| Ambroxol | Antitussives&Expectorants | 10 | | | |
| Cloperastine | Antitussives&Expectorants | 10 | | | |
| Eprazinone | Antitussives&Expectorants | 250 | | | |
| Phenacetin | Antitussives&Expectorants | 10 | | | |
| Hydrocortisone | Steroids | 10 | | | |
| Dexamethasone | Steroids | 50 | | | |
| Triamcinolone | Steroids | 50 | | | |
| Cortisone | Steroids | 10 | | | |
| Betamethasone | Steroids | 10 | | | |
| Methylprednisolone | Steroids | 20 | | | |
| Prednisolone | Steroids | 20 | | | |
| Prednisone | Steroids | 10 | | | |
| Chloropretadalafil | Other | 10 | | | |
| Desmethylsildenafil | Other | 100 | | | |
| Desmethylacetildenafil | Other | 10 | | | |
| Diethylpropion | Other | 10 | | | |
| Fenfluramine | Other | 10 | | | |

-END-

Unless otherwise stated the results shown in this test report refer only to the sample(s) tested. This test report cannot be reproduced, except in full, without prior written permission of the Company. 除非另有說明，此報告結果僅對測試的樣品負責。本報告未經本公司書面許可，不可部份複製。

This document is issued by the Company subject to its General Conditions of Service printed overleaf, available on request or accessible at www.sgs.com/terms_and_conditions.htm and, for electronic format documents, subject to Terms and Conditions for Electronic Documents at www.sgs.com/terms_e-document.htm. Attention is drawn to the limitation of liability, indemnification and jurisdiction issues defined therein. Any holder of this document is advised that information contained hereon reflects the Company's findings at the time of its intervention only and within the limits of Client's instructions, if any. The Company's sole responsibility is to its Client and this document does not exonerate parties to a transaction from exercising all their rights and obligations under the transaction documents. This document cannot be reproduced except in full, without prior written approval of the Company. Any unauthorized alteration, forgery or falsification of the content or appearance of this document is unlawful and offenders may be prosecuted to the fullest extent of the law.

VIAVIENTE GLOBAL

REPORT NO: FA/2011/51208A-01

Date: 2011/05/23



Sample Photo



Unless otherwise stated the results shown in this test report refer only to the sample(s) tested. This test report cannot be reproduced, except in full, without prior written permission of the Company. 除非另有說明，此報告結果僅對測試的樣品負責。本報告未經本公司書面許可，不可部份複製。

This document is issued by the Company subject to its General Conditions of Service printed overleaf, available on request or accessible at www.sgs.com/terms_and_conditions.htm and, for electronic format documents, subject to Terms and Conditions for Electronic Documents at www.sgs.com/terms_e-document.htm. Attention is drawn to the limitation of liability, indemnification and jurisdiction issues defined therein. Any holder of this document is advised that information contained hereon reflects the Company's findings at the time of its intervention only and within the limits of Client's instructions, if any. The Company's sole responsibility is to its Client and this document does not exonerate parties to a transaction from exercising all their rights and obligations under the transaction documents. This document cannot be reproduced except in full, without prior written approval of the Company. Any unauthorized alteration, forgery or falsification of the content or appearance of this document is unlawful and offenders may be prosecuted to the fullest extent of the law.